Royalty Pharma plc Provision for Other Credit Losses
Royalty Pharma plc (RPRX) reported Provision for Other Credit Losses of $268.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForOtherCreditLosses · last filed 2026-08-05
- Royalty Pharma plc provision for other credit losses for the quarter ending 2026-06-30 was $268.22M.
- Royalty Pharma plc provision for other credit losses for the quarter ending 2026-03-31 was -$197.49M.
- Royalty Pharma plc provision for other credit losses for the quarter ending 2025-12-31 was $23.11M, a 85.91% decline year-over-year.
- Royalty Pharma plc provision for other credit losses for the quarter ending 2025-09-30 was $12.13M.
- Royalty Pharma plc provision for other credit losses for fiscal 2025 was -$295.84M, a 140.39% decline from fiscal 2024.
- Royalty Pharma plc provision for other credit losses for fiscal 2024 was $732.46M, a 30.64% increase from fiscal 2023.
- Royalty Pharma plc provision for other credit losses for fiscal 2023 was $560.66M, a 38.00% decline from fiscal 2022.
- Royalty Pharma plc provision for other credit losses for fiscal 2022 was $904.24M, a 99.68% increase from fiscal 2021.
| Period end | Provision for Other Credit Losses 3 month | Provision for Other Credit Losses 6 month | Provision for Other Credit Losses 9 month | Provision for Other Credit Losses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $268.22M 10-Q · filed 2026-08-05 | $70.73M 10-Q · filed 2026-08-05 | $93.84M derived: sum of 3 quarters · filed 2026-08-05 | $105.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$197.49M 10-Q · filed 2026-05-06 | -$174.38M derived: sum of 2 quarters · filed 2026-05-06 | -$162.25M derived: sum of 3 quarters · filed 2026-05-06 | -$366.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $23.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $35.24M derived: sum of 2 quarters · filed 2026-02-11 | -$168.70M derived: sum of 3 quarters · filed 2026-08-05 | -$295.84M 10-K · filed 2026-02-11 |
| 2025-09-30 | $12.13M 10-Q · filed 2025-11-05 | -$191.80M derived: sum of 2 quarters · filed 2026-08-05 | -$318.94M 10-Q · filed 2025-11-05 | -$154.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$203.94M 10-Q · filed 2026-08-05 | -$331.08M 10-Q · filed 2026-08-05 | -$167.04M derived: sum of 3 quarters · filed 2026-08-05 | -$394.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$127.14M 10-Q · filed 2026-05-06 | $36.90M derived: sum of 2 quarters · filed 2026-05-06 | -$190.71M derived: sum of 3 quarters · filed 2026-05-06 | $21.72M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $164.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$63.57M derived: sum of 2 quarters · filed 2026-02-11 | $148.86M derived: sum of 3 quarters · filed 2026-02-11 | $732.46M 10-K · filed 2026-02-11 |
| 2024-09-30 | -$227.60M 10-Q · filed 2025-11-05 | -$15.18M derived: sum of 2 quarters · filed 2025-11-05 | $568.42M 10-Q · filed 2025-11-05 | $491.91M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $212.43M 10-Q · filed 2025-08-06 | $796.03M 10-Q · filed 2025-08-06 | $719.52M derived: sum of 3 quarters · filed 2026-02-11 | $996.65M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $583.60M 10-Q · filed 2025-05-08 | $507.09M derived: sum of 2 quarters · filed 2026-02-11 | $784.22M derived: sum of 3 quarters · filed 2026-02-11 | $1.03B derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | -$76.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $200.62M derived: sum of 2 quarters · filed 2026-02-11 | $441.85M derived: sum of 3 quarters · filed 2026-02-11 | $560.66M 10-K · filed 2026-02-11 |
| 2023-09-30 | $277.14M 10-Q · filed 2024-11-06 | $518.37M derived: sum of 2 quarters · filed 2024-11-06 | $637.17M 10-Q · filed 2024-11-06 | $946.02M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $241.23M 10-Q · filed 2024-08-08 | $360.03M 10-Q · filed 2024-08-08 | $668.88M derived: sum of 3 quarters · filed 2025-02-12 | $973.94M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $118.80M 10-Q · filed 2024-05-09 | $427.65M derived: sum of 2 quarters · filed 2025-02-12 | $732.71M derived: sum of 3 quarters · filed 2025-02-12 | $838.43M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $308.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $613.91M derived: sum of 2 quarters · filed 2025-02-12 | $719.62M derived: sum of 3 quarters · filed 2025-02-12 | $904.24M 10-K · filed 2025-02-12 |
| 2022-09-30 | $305.06M 10-Q · filed 2023-11-08 | $410.77M derived: sum of 2 quarters · filed 2023-11-08 | $595.40M 10-Q · filed 2023-11-08 | $861.90M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $105.71M 10-Q · filed 2023-08-08 | $290.33M 10-Q · filed 2023-08-08 | $556.84M derived: sum of 3 quarters · filed 2024-02-15 | $694.68M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $184.62M 10-Q · filed 2023-05-09 | $451.13M derived: sum of 2 quarters · filed 2024-02-15 | $588.96M derived: sum of 3 quarters · filed 2024-02-15 | $345.20M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $266.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $404.34M derived: sum of 2 quarters · filed 2024-02-15 | $160.58M derived: sum of 3 quarters · filed 2024-02-15 | $452.84M 10-K · filed 2024-02-15 |
| 2021-09-30 | $137.84M 10-Q · filed 2022-11-08 | -$105.92M derived: sum of 2 quarters · filed 2022-11-08 | $186.34M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$243.76M 10-Q · filed 2022-08-04 | $48.50M 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | $230.84M 10-K · filed 2023-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |